Published in Acad Radiol on January 13, 2010
Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging (2013) 1.54
Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol (2011) 1.25
DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med (2013) 1.19
Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy. Transl Oncol (2013) 0.97
Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol (2010) 0.93
A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation. Magn Reson Imaging (2014) 0.86
Correction of arterial input function in dynamic contrast-enhanced MRI of the liver. J Magn Reson Imaging (2012) 0.86
Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging (2015) 0.81
Assessment of repeatability and treatment response in early phase clinical trials using DCE-MRI: comparison of parametric analysis using MR- and CT-derived arterial input functions. Eur Radiol (2015) 0.78
A comparison of individual and population-derived vascular input functions for quantitative DCE-MRI in rats. Magn Reson Imaging (2014) 0.77
Techniques and applications of dynamic contrast enhanced magnetic resonance imaging in cancer. Conf Proc IEEE Eng Med Biol Soc (2014) 0.76
Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling. J Magn Reson (2016) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med (1998) 20.81
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med (2006) 3.63
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging (2003) 2.77
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology (2003) 2.31
Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med (1995) 2.10
Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging (1999) 2.07
Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology. J Magn Reson Imaging (2006) 1.94
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66
Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer (1994) 1.65
Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol (2000) 1.54
Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging (1997) 1.39
Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med (2005) 1.38
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate (2005) 1.35
Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology (1997) 1.32
Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. Magn Reson Med (2009) 1.30
Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging--initial experience. Radiology (2004) 1.29
Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging (2001) 1.25
Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology (1987) 1.15
Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology (2001) 1.10
Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging (1999) 1.08
Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res (1997) 1.04
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology (1996) 1.01
Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging (1998) 0.89
Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J Urol (1992) 0.87
Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging. Eur J Radiol (2002) 0.83
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
A comparison of two time intervals for test-retest reliability of health status instruments. J Clin Epidemiol (2003) 3.65
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol (2013) 2.59
The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg Am (2005) 2.56
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int (2013) 2.38
Beliefs and attitudes of members of the American Academy of Orthopaedic Surgeons regarding the treatment of anterior cruciate ligament injury. Arthroscopy (2003) 2.06
Uterine arteriovenous malformations: from diagnosis to treatment. J Ultrasound Med (2006) 2.01
Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology. J Magn Reson Imaging (2006) 1.94
Bacterial sepsis after prostate biopsy--a new perspective. Urology (2009) 1.91
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.85
Phyllodes tumor of the prostate: long-term followup study of 23 cases. J Urol (2004) 1.77
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68
Imaging assessment of congenital and acquired abnormalities of the portal venous system. Radiographics (2011) 1.65
Structural basis of microRNA length variety. Nucleic Acids Res (2010) 1.56
Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs (2002) 1.54
Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer. BJU Int (2007) 1.52
Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. Oncol Nurs Forum (2003) 1.50
Myelin water imaging of multiple sclerosis at 7 T: correlations with histopathology. Neuroimage (2008) 1.47
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res (2011) 1.42
Dysmetabolic hyperferritinemia is associated with normal transferrin saturation, mild hepatic iron overload, and elevated hepcidin. Ann Hematol (2010) 1.38
Measuring improvement following total hip and knee arthroplasty using patient-based measures of outcome. J Bone Joint Surg Am (2005) 1.37
Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. Hum Genet (2010) 1.34
Chondral resurfacing of articular cartilage defects in the knee with the microfracture technique. Surgical technique. J Bone Joint Surg Am (2006) 1.32
Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res (2011) 1.29
Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate (2002) 1.28
Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys (2013) 1.25
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Measurement of shoulder activity level. Clin Orthop Relat Res (2005) 1.24
Variation in orthopaedic surgeons' perceptions about the indications for rotator cuff surgery. J Bone Joint Surg Am (2005) 1.19
Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int (2011) 1.15
Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleic Acids Res (2003) 1.14
Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res (2004) 1.13
Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer. Cancer Nurs (2007) 1.12
Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer (2008) 1.12
Human enhancer of rudimentary is a molecular partner of PDIP46/SKAR, a protein interacting with DNA polymerase delta and S6K1 and regulating cell growth. FEBS J (2006) 1.11
The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci (2011) 1.11
A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci (2006) 1.09
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
Effect of acetabular labral tears, repair and resection on hip cartilage strain: A 7T MR study. J Biomech (2009) 1.06
International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int (2007) 1.02
Intermittent androgen suppression for prostate cancer. Nat Rev Urol (2010) 1.01
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res (2012) 1.01
Patients' expectations of shoulder surgery. J Shoulder Elbow Surg (2002) 1.00
Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology (2002) 1.00
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res (2008) 0.99
Ciz1, a p21 cip1/Waf1-interacting zinc finger protein and DNA replication factor, is a novel molecular partner for human enhancer of rudimentary homolog. FEBS J (2007) 0.99
Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int (2011) 0.99
Mathematical modelling of prostate cancer growth and its application to hormone therapy. Philos Trans A Math Phys Eng Sci (2010) 0.99
Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. BJU Int (2012) 0.99
Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int (2011) 0.98
Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res (2004) 0.98
Copy number variation of microRNA genes in the human genome. BMC Genomics (2011) 0.97
Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl (2012) 0.95
Caspase-dependent cleavage of carbamoyl phosphate synthetase II during apoptosis. Mol Pharmacol (2002) 0.93
Device for sectioning prostatectomy specimens to facilitate comparison between histology and in vivo MRI. J Magn Reson Imaging (2010) 0.93
CAG and CTG repeat polymorphism in exons of human genes shows distinct features at the expandable loci. Hum Mutat (2007) 0.90
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer (2011) 0.90
Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology. Mult Scler (2010) 0.89
Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example. ScientificWorldJournal (2010) 0.89
A classification of spin frustration in molecular magnets from a physical study of large odd-numbered-metal, odd electron rings. Proc Natl Acad Sci U S A (2012) 0.89
The role of resection of pulmonary metastases from prostate cancer: a case report and literature review. Can Urol Assoc J (2011) 0.88
The association between hospital volume and total shoulder arthroplasty outcomes. Clin Orthop Relat Res (2005) 0.87
Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe. Nanomedicine (2011) 0.87
Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy. Magn Reson Imaging (2010) 0.86
Measurement of factors influencing the participation of patients with prostate cancer in clinical trials: a Canadian perspective. BJU Int (2007) 0.86
Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol (2002) 0.86
Malignant degeneration of a lumbar osteochondroma into a chondrosarcoma which mimicked a large retropertioneal mass. Skeletal Radiol (2012) 0.84
Pathological correlates of magnetic resonance imaging texture heterogeneity in multiple sclerosis. Ann Neurol (2013) 0.84
Identification and functional analysis of the erh1(+) gene encoding enhancer of rudimentary homolog from the fission yeast Schizosaccharomyces pombe. PLoS One (2012) 0.84
Multiparametric MRI maps for detection and grading of dominant prostate tumors. J Magn Reson Imaging (2012) 0.84
Radiation dose in abdominal computed tomography: the role of patient size and the selection of tube current. Can Assoc Radiol J (2006) 0.84
Cardiometabolic risk factors in experimental spinal cord injury. J Neurotrauma (2010) 0.83
How 'male health' fits into the field of urology. Nat Rev Urol (2013) 0.82
Registration of whole-mount histology and volumetric imaging of the prostate using particle filtering. IEEE Trans Med Imaging (2014) 0.82
Diffusion-weighted MRI in prostate cancer -- comparison between single-shot fast spin echo and echo planar imaging sequences. Magn Reson Imaging (2007) 0.82
Recurrent ectopic pancreatitis of the jejunum and mesentery over a 30-year period. Hepatobiliary Pancreat Dis Int (2011) 0.82